Aurobindo Plans to Invest $31.7 Million for New Facility in North Carolina
Aurobindo Pharma USA, Inc., a subsidiary of the pharmaceutical company, Aurobindo Pharma Limited, headquartered in Hyderabad, India, plans to invest $31.7 million in a new national headquarters in Durham, North Carolina, for specialty pharmaceutical R&D, according to the Governor’s Office of North Carolina. The new facility will create 275 new R&D and pharmaceutical manufacturing jobs to Durham. Aurobindo Pharma USA is based in Dayton, New Jersey.
The company's North Carolina expansion will be facilitated, in part, by an award to the company from the state's Job Development Investment Grant (JDIG) program, which was approved by the state's Economic Investment Committee. Under the terms of the company's JDIG, Aurobindo Pharma USA is eligible to receive up to $3.8 million in total reimbursements. Payments will occur in annual installments over 12 years pending verification by NC Commerce and NC Revenue that the company has met incremental job creation and investment targets. JDIGs reimburse new and expanding companies a portion of the newly created tax-base with the goal of increasing the overall tax benefit to the State of North Carolina. This JDIG is contingent upon the approval of an appropriate match by local governments or organizations.
Aurobindo now operates two facilities in central New Jersey, with approximately 300,000 square feet of laboratory, manufacturing, distribution, and administrative space .